What does the evidence say about Polydextrose Gut Microbiota Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Polydextrose Gut Microbiota Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Results Supplementation with RS, but not PD, increased a range of conjugated BAs and deoxycholic acid (FDR Conclusion RS increased plasma BAs, particularly conjugated BAs, whereas PD reduced faecal secondary BA transformation. [Fan J (2026); evidence level 2] - Purpose Dietary fibre may influence bile acid (BA) metabolism via interactions with gut microbiota. [Fan J (2026); evidence level 2] - We hypothesised that dietary fibres with distinct fermentative properties, resistant starch (RS) and polydextrose (PD), would differentially alter BA profiles in plasma and faeces through gut microbiota-mediated mechanisms. [Fan J (2026); evidence level 2] - According to the global disease burden database, the number of patients with IBD increased from 3.32 million in 1990 to 4.9 million in 2019. [Kong Yan (2026); evidence level 4] - The area with the highest prevalence rate is high-income North America, where the low-fiber and high-fat diet pattern is an important risk factor for IBD (,). [Kong Yan (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.